Skip to main content

Veradermics, Inc

MANE
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0001827635

In the last 90 days, Veradermics, Inc insiders filed 0 open-market purchases and 4 sales; 164 institutions reported holding it in 13F filings for Q2 2026, worth $4.17B in total; superinvestors Viking Global Investors and Maverick Capital hold it.

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $103.1M in total
4
13F holdersQ2 2026, +83 vs. previous quarter
164
13F valueReported value at the end of Q2 2026
$4.17B
Superinvestors holdingAt the end of Q2 2026
2

Price chart

Superinvestors holding MANE, Q2 2026

2 superinvestors report holding Veradermics, Inc on Form 13F. Percentages are the stock's share of each portfolio.

Go to the superinvestors tab

Viking Global Investors

Andreas Halvorsen

0.5%

Veradermics, Inc's share of the portfolio

Shares
1,561,494
Value
$192.0M

Maverick Capital

Lee Ainslie

0.9%

Veradermics, Inc's share of the portfolio

Shares
789,980
Value
$97.1M

Latest insider trades

Open-market purchases and sales by Veradermics, Inc insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 21, 2026 (view filing)6:11 PM ETAug 192 daysMontanova Capital, LLC and 3 othersDirectorSSaleCommon stock, par value $0.00001 per share−750.0K$107.25−$80.4M−61.9%461.0K after2 lots
Aug 18, 2026 (view filing)9:10 PM ETAug 171 dayDurso Timothy AugustChief Technical OfficerSSale−43.5K$107.82−$4.69M−35.8%78.1K after5 lots10b5-1
Aug 18, 2026 (view filing)9:04 PM ETAug 171 dayWaldman Reid AlexanderChief Executive OfficerSSale−67.5K$107.86−$7.28M−28.3%170.8K after5 lots10b5-1
Aug 14, 2026 (view filing)6:01 PM ETAug 122 daysChilds John WDirectorSSale−100.0K$107.12−$10.7M−34.0%194.1K after3 lots
Feb 27, 2026 (view filing)Feb 522 daysChilds John WDirectorPPurchase+294.1K$17.00+$5.00MNew position294.1K afterAmended
Feb 9, 2026 (view filing)6:28 PM ETFeb 4-65 daysLateMontanova Capital, LLC and 3 othersDirector, 10% OwnerPPurchaseCommon stock, par value $0.00001 per share+282.7K$37.30+$10.5M+118.9%520.5K after19 lots
Feb 5, 2026 (view filing)7:03 PM ETFeb 5Same dayLongitude Venture Partners V, L.P. and 3 others10% OwnerPPurchase+1.07M$17.00+$18.3M+109.9%2.05M after2 lotsDuplicate filing
Feb 5, 2026 (view filing)Feb 5Same dayCoric VladDirectorPPurchase+117.6K$17.00+$2.00M+58.3%319.4K after2 lots
Feb 5, 2026 (view filing)Feb 5Same dayEnright Patrick GDirector, 10% OwnerPPurchase+1.07M$17.00+$18.3M+109.9%2.05M after2 lots

Top 10 13F holders, Q2 2026

The largest institutional positions in Veradermics, Inc at the end of Q2 2026; share changes are against Q1 2026.

See all 164 holders
Institutions holding MANE in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Suvretta Capital Management, LLC4,168,970$512.5M10.77%00.0%Unchanged
FMR LLC3,204,981$394.0M0.02%+1,412,072+78.8%Added
Sr One Capital Management, LP2,401,868$295.3M28.42%00.0%Unchanged
Deep Track Capital, LP2,000,000$245.9M3.62%+1,500,000+300.0%Added
Citadel Advisors LLC1,877,775$230.9M0.13%+52,103+2.9%Added
Siren, L.L.C.1,655,374$203.5M4.13%+150,000+10.0%Added
BlackRock, Inc.1,593,791$195.9M0.00%+1,311,180+464.0%Added
Viking Global Investors LPSuperinvestorViking Global Investors1,561,494$192.0M0.55%−129,061−7.6%Reduced
JPMorgan Chase & Co1,165,584$144.2M0.01%+189,418+19.4%Added
Standard Life Aberdeen plc1,096,642$134.8M0.19%+41,982+4.0%Added